600267 Stock Overview
Engages in the research, development, production, and sale of biological and generic drugs in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 600267 from our risk checks.
Zhejiang Hisun Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥8.35 |
| 52 Week High | CN¥10.56 |
| 52 Week Low | CN¥6.43 |
| Beta | 0.38 |
| 11 Month Change | -1.76% |
| 3 Month Change | 13.61% |
| 1 Year Change | -20.02% |
| 33 Year Change | -36.89% |
| 5 Year Change | -21.00% |
| Change since IPO | 41.77% |
Recent News & Updates
Recent updates
Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Shares Lagging The Industry But So Is The Business
Sep 26
These 4 Measures Indicate That Zhejiang Hisun Pharmaceutical (SHSE:600267) Is Using Debt Reasonably Well
Apr 30Investors Don't See Light At End Of Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Tunnel
Mar 29Shareholder Returns
| 600267 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -1.2% | -1.5% | -2.1% |
| 1Y | -20.0% | -9.4% | 2.8% |
Return vs Industry: 600267 underperformed the CN Pharmaceuticals industry which returned -9.4% over the past year.
Return vs Market: 600267 underperformed the CN Market which returned 2.8% over the past year.
Price Volatility
| 600267 volatility | |
|---|---|
| 600267 Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 600267 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600267's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1956 | 8,062 | Kevin Xiao | www.hisunpharm.com |
Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biological and generic drugs in China. The company provides active pharmaceutical ingredients and finished dosage form products. It offers products for anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressant, liver care, and orthopaedics treatment; and weight loss, anti-viral, anti-TB, animal healthcare, and others.
Zhejiang Hisun Pharmaceutical Co., Ltd. Fundamentals Summary
| 600267 fundamental statistics | |
|---|---|
| Market cap | CN¥9.83b |
| Earnings (TTM) | -CN¥20.24m |
| Revenue (TTM) | CN¥9.55b |
1.0x
P/S Ratio-485.8x
P/E RatioIs 600267 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600267 income statement (TTM) | |
|---|---|
| Revenue | CN¥9.55b |
| Cost of Revenue | CN¥5.84b |
| Gross Profit | CN¥3.70b |
| Other Expenses | CN¥3.72b |
| Earnings | -CN¥20.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.017 |
| Gross Margin | 38.78% |
| Net Profit Margin | -0.21% |
| Debt/Equity Ratio | 54.6% |
How did 600267 perform over the long term?
See historical performance and comparison